HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use DILANTIN-125® safely and effectively. See full prescribing information for DILANTIN-125®.
DILANTIN-125® (phenytoin) oral suspension
Initial U.S. Approval: 1953
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
DILANTIN is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
DILANTIN-125 is available as a 125 mg phenytoin/5 mL oral suspension. (3)
WARNINGS AND PRECAUTIONS
The most common adverse reactions are nervous system reactions, including nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Did you find an answer to your question?